bluuebunny/crossref_metadata_2025_split huggingface dataset:
Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy
Authors: Thatcher N. , Palmer M. K. , Swindell R. , Crowther D. 
Published: February 2007

AbstractThirty‐eight patients with metastatic melanoma were evaluated immunologically prior to chemoimmunotherapy. The assays used included recall antigen skin hypersensitivity; lymphocyte count; nonspecific T, non‐T, and K cell lymphocytotoxicity; and T and B cell rosette enumeration.Survival curves were computed for each of four ranges of values of a given immunologic test. The higher ranges of positive skin tests, lymphocyte count, cytotoxicity, and T and B subpopulation numbers were consistently associated with the longer survivals. The differences reached statistical significance for non‐T cell cytotoxicity and B and T cell peripheral blood counts.Pretreatment immune reactivity, particularly that involving non‐T cell function, appears related to length of survival.
Fluorometric determinations of the relative immunoglobulin content of plasma cells of patients with monoclonal gammopathy
Authors: Kühner Ulrich , Barandun Silvio , Morell Andreas , Riesen Walter , Skvaril Frantisek , Wagner Hans P. 
Published: February 2007

AbstractThe relative cytoplasmic immunoglobulin content of fixed plasma cells taken from the bone marrow of five patients with myeloma and five patients with benign monoclonal gammopathy was determined with a microscope fluoro‐meter. In eight of the ten plasma cell populations studied, the distribution of the fluorescence intensities was close to normal. In three of these eight populations a significant difference in the variances of the heavy and light chain fluorescence intensities was found. Variances of heavy and light chain fluorescence intensities were smaller in patients with an immunoglobulin A‐type gammopathy than in those with an immunoglobulin G‐type gammopathy. No difference was found if normalized relative frequency distribution patterns of heavy or light chain fluorescence intensities of patients with myeloma were compared with those of patients with benign monoclonal gammopathies.
A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients
Authors: Rossof Arthur H. , Kerr Robert O. , Braine Hayden G. , Coltman Charles A. 
Published: February 2007

AbstractThree patients with Hodgkin disease, eight with non‐Hodgkin lymphoma, and one with chronic lymphocytic leukemia refractory to conventional combination chemotherapy were treated for remission induction with a new kinetically designed four‐drug combination consisting of bleomycin, vincristine, adriamycin, and prednisone and given the acronym “BOAP.” Eight patients had prior radiotherapy, including two who had total nodal irradiation. Eight patients (all three with Hodgkin disease and five of eight with non‐Hodgkin lymphoma) achieved complete remission (73% of the lymphoma patients). An additional two patients with non‐Hodgkin lymphoma sustained partial remissions, for an overall response rate of 91%.Toxicity caused the interruption of therapy in three patients and an additional patient might have sustained a drug‐related death. This study compares favorably with other studies investigating primary or secondary combination chemotherapy of advanced lymphomas.
Central nervous system tumors of childhood treated with CCNU, vincristine, and radiation
Authors: Ward H. W. C. 
Published: February 2007

AbstractCCNU was used in the treatment of 18 patients with childhood tumors of the CNS. Severe bone‐marrow toxicity was noted. The initial dose was 130 mg/m2 given every 6 weeks, but it was often necessary to reduce the dose and prolong the interval between doses. The toxicity appeared to be much the same whether previous radiotherapy had been given to the whole CNS or to the brain only.In assessable patients with pure medulloblastoma, three out of three showed marked responses to CCNU. In those with a mixture of medulloblastoma and other tumor components, two out of two showed responses to CCNU. In children with astrocytomata of various types, only two out of six showed responses to CCNU, and in these the degree of response was slight. The results suggest that CCNU is a useful treatment for medulloblastoma but its value in the treatment of childhood astrocytoma is uncertain. In 6 patients who received both radiotherapy and CCNU, the contribution of the CCNU was not assessable.
Normal urinary excretion of catecholamine catabolites in children with retinoblastoma
Authors: Orlowski James P. , Levin Howard S. , Price Ronald L. , Dyment Paul G. 
Published: February 2007

AbstractUrinary catecholamine catabolites, homovanillic acid, vanillylmandelic acid, total metanephrines, and total catecholamines were assayed in 12 patients with newly diagnosed retinoblastoma prior to surgery and treatment. These values were within normal limits for the ages of all 12 patients, including one with metastases to brain, liver, lymph nodes, and bone marrow. The predictive value and efficiency of these tests in the diagnosis of retinoblastoma are insufficient to warrant their continued use on a routine basis.
Plasmacytomas and mesothelioma
Authors: Perry Michael C. , Solinger Alan , Farhangi Mehdi , Luger Alan 
Published: February 2007

AbstractA patient is reported who developed five plasmacytomas over a four‐year period and developed a pleural mesothelioma 12 years later. The relationship of these two entities is discussed and the question of a common environmental carcinogen is raised.
Prolonged survival in chronic lymphocytic leukemia: A case report
Authors: Reynolds Colonel Ralph D. , Horne Major McDonald K. , Greenberg Bernard R. , Mackenzie Malcolm R. , Binder Henry J. , Chang R. Shihman , Lawrence John H. 
Published: February 2007

AbstractA patient with long‐standing chronic lymphocytic leukemia with both humoral and cellular immunodeficiency had lymph node receptor evidence of a B lymphocyte disorder. He was also found to secrete the Epstein–Barr virus and, late in his illness, developed a markedly positive antinuclear antibody. Interrelationship of these findings may be important in the ultimate determination of the etiology and functional mechanisms in lymphocyte malignancies.
Childhood multifocal osteosarcoma—diagnosis by 99m technetium bone scan: A case report
Authors: Mahoney Donald H. , Shepherd Dell A. , DePuey E. Gordon , Fernbach Donald J. 
Published: February 2007

AbstractA 14‐year‐old boy with osteosarcoma presented with evidence of a solitary bone lesion by clinical and radiographic examination. A preoperative 99mtechnetium bone scan revealed multiple skeletal osteoblastic abnormalities and upon biopsy of one of these lesions, the diagnosis of multifocal osteosarcoma was established. This unusual case dramatically illustrates the value of 99mtechnetium bone scan in preoperative staging of patients with osteosarcoma.
Idiotype in myeloma terminating in erythroleukemia
Authors: Barcos Maurice , Kim Seung , Seon Ben K. , Nussbaum Annie , Gailani Salman , Henderson Edward S. 
Published: February 2007

AbstractA patient with multiple myeloma, IgGK type, developed erythroleukemia with cytogenetic abnormalities three years after diagnosis. The latter disease progressed terminally to acute granulocytic leukemia. Anti‐idiotype antibody reagents were prepared by injecting rabbits with the purified monoclonal IgGK obtained from the patient's serum and subsequent absorption of the antisera with normal IgG coupled to Sepharose 4B. These reagents reacted specifically with autologous myeloma cells but failed to react with all tested allogeneic cells: these included myeloma cells, reactive lymphocytes and plasma cells, and established lymphoid cell lines. Common idiotypic determinants were found in lymphoid and plasmacytic cells of the patient's marrow, spleen, lymph node, and gastrointestinal tract at autopsy that were not present in the leukemic population. The findings indicate that myeloma and granulocytic leukemia cells have separate clonal origins.
Bone marrow chromosomes in acute lymphoblastic leukaemia: A long‐term study
Authors: Secker‐Walker Lorna M. , Swansbury G. J. , Lawler Sylvia D. , Hardisty R. M. 
Published: February 2007

AbstractThe bone marrow chromosomes of 25 children with acute lymphoblastic leukaemia (ALL) were examined at diagnosis before treatment, during remission, and in 12 cases, also during relapse. Follow‐up was for at least six years. At diagnosis, 17 patients had a major population of chromosomally abnormal cells and of these 11 had identifiable clones. The commonest abnormality was hyperdiploidy. Eight patients had predominantly normal cells, but four of these had a minor abnormal clone. In remission, some samples were completely normal but, when pooled, remission samples had a minor population of chromosomally aberrant cells which were rarely clonal. The incidence of structural abnormalities was the same in patients who ultimately relapsed and those who remained in first remission at the end of the study, but the presence of hyperdiploid cells and/or clones in remission was more frequently associated with subsequent relapse. Relapse patterns were of two kinds: in three patients there was a return of the chromosomal abnormalities seen at diagnosis; in six others, chromosomal features in relapse were distinct from those at diagnosis. It is suggested that relapse associated with distinct chromosomal features may represent malignant transformation of a previously unaffected cell line. While chromosomal abnormalities seen prior to treatment can be related to the leukaemic event alone, abnormalities seen in remission and in relapse may result partly from drug and X‐ray treatment. The relative importance of treatment and other factors to chromosomal change in ALL is discussed.
Leiomyosarcoma of the stomach: Results of surgery and chemotherapy in an eleven‐year‐old girl with liver metastases
Authors: Johnson Helen , Hutter John J. , Paplanus Samuel H. 
Published: February 2007

AbstractThis report describes an 11‐7/12‐year‐old girl with leiomyosarcoma of the stomach metastatic to liver who was treated with surgical resection and combination chemotherapy, which included adriamycin. She remains well 52 months after diagnosis and 27 months after cessation of chemotherapy. The favorable course of this patient suggests that aggressive adjuvant chemotherapy should be considered for patients with leiomyosarcoma who have poor prognostic features.
Osteosarcoma and acute myeloblastic leukemia after therapy for childhood Hodgkin disease ‐ A case report
Authors: Chan Ka Wah , Miller Denis R. , Tan Charlotte T. C. 
Published: February 2007

AbstractA child diagnosed with Stage IVB Hodgkin disease at nine and one‐half years of age subsequently developed osteosarcoma and acute myelogenous leukemia ten years after her initial diagnosis. She received multiple courses of radiotherapy and several single chemotherapeutic agents for her Hodgkin disease. Therapy‐induced multiple malignancies and intrinsic predisposition to carcinogenesis in this case is discussed.
Are growth rates of tumors of any clinical importance?
Authors: Mühe E. , Gall F. P. , Angermann B. 
Published: February 2007

AbstractThe tumor doubling times were determined in 142 rounded pulmonary lesions of 78 patients (13 bronchial carcinomas, 7 benign pulmonary tumors, and 122 pulmonary metastases). They varied between +12 and +8863 days of tumor growth and of ‐1810 days of decrease in tumor mass. Forty‐four percent of all pulmonary metastases doubled their volume within 60 to 250 days. The growth rates during the period of observation varied greatly in several pulmonary metastases of the same patient, even for the same solitary circular lung focus of the same person. There is no relationship between tumor doubling time and histological type of the tumor, nor between the interval between operative removal of the primary tumor and the occurrence of pulmonary metastases. In patients between the ages of 10 and 30 years only rapidly growing pulmonary metastases with a tumor doubling time of less than 60 days could be found; even though there is no proved relationship between growth rate and age. The tumor doubling time gives no useful information on the nature of a circular lung focus, and there are no clinical consequences for diagnosis.
Long‐term survivors of acute lymphoblastic leukemia — risk of relapse after cessation of therapy
Authors: Ravindranath Yaddanapudi , Soorya Dushyant T. , Schultz Gary E. , Lusher Jeanne M. 
Published: February 2007

AbstractThe results of cessation of therapy (COT) in 64 long‐term survivors (disease‐free survival of five years or more) of acute lymphoblastic leukemia (ALL) were analyzed to determine the incidence of relapse off therapy. Thirty‐seven of the patients had intermittent central nervous system (CNS) prophylaxis. Total follow‐up from diagnosis varied from 5.75 to 27.75 years. The median time off therapy was three years (range, 8 months to 26 years). Eighty‐six percent (55/64) of the patients continue in their initial remission. Eight patients had relapse, and one patient had a morphologically different leukemia at recurrence. All the relapses occurred between five to eight years from diagnosis and the cumulative rate of relapse for this period was 0.14. There was no significant difference in the rate of relapse for those receiving CNS prophylaxis (0.08) versus those not receiving CNS prophylaxis (0.19). The difference in the relapse rates for boys (0.24) versus girls (0.04) was statistically significant (P=0.04). Isolated testicular relapse (ITR) was not seen in any of the 34 boys.The present study confirms the earlier observations by others that relapse is uncommon in ALL patients remaining in remission longer than seven to eight years. ALL patients treated with intermittent CNS prophylaxis administered throughout the period of maintenance chemotherapy appear to be at no greater risk for relapse off therapy than those treated with high‐dose initial cranial irradiation and intrathecal methotrexate. The longer duration of therapy and the use of a repetitive reinduction regimen for maintainance seem to be associated with a decreased risk of ITR after discontinuation of therapy for boys and men. There appears to be a small but definite risk of “second” leukemia in the long‐term survivors of leukemia.
Hodgkin disease following acute lymphocytic leukemia in a patient from a cancer‐prone family: A case report
Authors: Horbar Jeffrey D. , Dickerman Joseph D. , Allen Elizabeth F. , Albertini Richard J. 
Published: February 2007

AbstractA person with acute lymphocytic leukemia who developed Hodgkin disease is described. His family had an excessive number of members with cancer. This paper describes various laboratory investigations, which were done in an attempt to elucidate certain host factors that might have been responsible for the increased incidence of cancer in this family.
Low‐ and high‐risk non‐T non‐B and T‐cell acute lymphoid leukemia (ALL) in childhood: Different duration of remission and survival
Authors: Imbach P. , Baumgartner C. , Berchtold W. , Gautier E. , Gugler E. , Hirt A. , Morell A. , Tönz O. , Wyss M. , Zurbrügg R. , Wagner H. P. 
Published: February 2007

AbstractIn a prospective, nonrandomized trial clinical (initial WBC and chest film) and immunological (surface immunoglobulin and rosetting with pretreated sheep red blood cells) criteria were used to stratify 69 children with previously untreated acute lymphoid leukemia (ALL). Forty of 61 evaluable patients had low‐risk ALL (initial WBC ≤ 20,000/mm3, no mediastinal mass) and were treated less intensively. Twenty‐one of 61 patients had high‐risk ALL (initial WBC > 20,000/mm3 and/or mediastinal mass) and were treated more intensively. Of the high‐risk patients 15 had non‐T non‐B and 6 T ALL. Sixty of 61 patients went into complete remission. After a median observation period of 27 months, 32 of 40 low‐risk, 7 of 14 high‐risk non‐T non‐B, and none of 6 high‐risk T ALL patients were in continuous first remission. Thrity‐six of 40 low‐risk, 9 of 15 high‐risk non‐T non‐B, and none of 6 T ALL patients were alive. Despite more intensive treatment, the duration of remission and the survival were significantly shorter in the high‐risk than in the low‐risk patients. Among the high‐risk ALL, non‐T non‐B ALL did better than T ALL.
Fulminant lung metastases from cancer of the breast
Authors: Nixon Daniel W. , Shlaer Stephen M. 
Published: February 2007

AbstractFulminant, rapidly fatal pulmonary metastatic disease occurred in two breast cancer patients. The radiologic appearance in both suggested infection. Immunosuppresion may have contributed to this overwhelming illness. Attempts to obtain a tissue diagnosis are warranted in cancer patients if acute pulmonary infiltrates do not respond to appropriate antibiotics.
Nucleoside phosphorylase activity in normal and leukemic cells
Authors: Ben‐Bassat Isaac , Brok‐Simoni Frida , Holtzman Fanny , Ramot Bracha 
Published: February 2007

AbstractNucleoside phosphorylase (NP) activity was assayed in normal peripheral blood lymphocytes, mature and immature thymocytes fractionated by peanut agglutinability, CLL lymphocytes, and ALL lymphoblasts to determine applicability as an enzymatic cell marker. Circulating lymphocytes had the highest activity, immature thymocytes the lowest, and mature thymocytes were intermediate in NP level. This suggests an increase in NP activity with T‐cell maturation. CLL lymphocytes showed very low activity, confirming previous reports. However, the NP activity of the lymphoblasts of 40 patients with B, T, and non‐B, non‐T ALL was similar to that of normal peripheral blood lymphocytes and could not be used to discriminate between these subgroups of ALL.
Relapse in childhood acute lymphoblastic leukemia after elective cessation of initial treatment: Failure of subsequent treatment with cyclophosphamide, cytosine arabinoside, vincristine and prednisone (COAP)
Authors: Sallan Stephen E. , Hitchcock‐Bryan Suzanne 
Published: February 2007

AbstractAlthough the majority of children with acute lymphoblastic leukemia (ALL) can electively stop treatment after 21/2–5 years of continuous disease‐free remission, 20–25% of those patients relapse after discontinuation of therapy. We treated 15 patients whose disease recurred after stopping treatment. Fourteen of them attained complete remission, but the median duration of disease‐free survival was only 11 months. In this population, the site of initial relapse, bone marrow or testicle, did not influence subsequent outcome. Patients who relapsed within six months of stopping initial therapy had shorter second remissions than those who relapsed after six months.We conclude that the combination chemotherapy utilized in this study was inadequte for the control of relapsed ALL. Future programs will have to use different drug combinations or bone marrow transplantation.
Low‐dose adriamycin remission maintenance for advanced acute lymphoblastic leukemia: A southwest oncology group study
Authors: Hvizdala Eva , Komp Diane , Ragab Abdel , Crist William , Chu Jen‐Yih 
Published: February 2007

AbstractA low‐dose maintenance schedule of adriamycin was evaluated in children with advanced acute lymphoblastic leukemia. Thirty‐six evaluable patients who achieved two or more remissions were given adriamycin, 10 mg/m2/week, as a single maintenance agent. The median duration of second remission was 17 weeks, but only 5 weeks for third and fourth remission. Although the therapy was not found effective in more advanced disease, the median duration of second remission approached that obtained from various multi‐agent treatment schedules. We conclude that the therapeutic efficacy of this treatment schedule makes it appealing for incorporation into multi‐drug combination regimens.
Unusual cause of increased intracranial pressure from metastatic germ cell cancer
Authors: Scalzo Anthony J. , Comis Robert L , Ginsberg Sandra J. , Tinsley Roger 
Published: February 2007

AbstractMetastatic lesions within the brain parenchyma are usually responsible for the development of increased intracranial pressure in patients with metastatic cancer. The lesions can usually be easily documented by computerized axial tomography (CT) of the head. Other causes must be sought in patients with metastatic cancer who present with signs of increased intracranial pressure and whose CT scan of the head fails to reveal any parenchymal lesions. Cranial metastases obstructing venous outflow from the brain may present in this manner.
Vindesine: A phase II study in childhood malignancies‐A report for cancer and leukemia group B
Authors: Ettinger Lawrence J. , Brecher Martin , Coleman Morton , Smithson W. Anthony , Patterson Richard , Russell E. Clifton , Necheles Thomas , Jones Barbara , Ohnuma Takao 
Published: February 2007

AbstractVindesine, a semisynthetic derivative of vinblastine sulfate, was tested for anti‐tumor activity and clinical toxicity in 36 children. The drug was administered to the initial 13 patients entered into the study a 2 mg/m2/day for five days by IV bolus. Because of severe neurotoxicity and life‐threatening gastrointestinal toxicity, the regimen in 23 patients was modified to 4 mg/m2 IV infusion over four hours, weekly. This latter regimen was well tolerated, with acceptable gastrointestinal, hematological, and neurotoxicity. One child with acute lymphocytic leukemia resistant to vincristine had a transient Ml remission bone marrow. Improvement or stable disease was noted in one patient each with Ewing's sarcoma, neuroblastoma, and Hodgkin's disease.
Meningeal carcinomatosis in small cell carcinoma of the lung
Authors: Oster Martin W. , Fetell Michael 
Published: February 2007

AbstractSmall cell carcinoma of the lung is extremely sensitive to chemotherapy and radiation therapy. We describe the case of a patient who had a complete response to such treatment but relapsed with meningeal carcinomatosis. We propose that prophylactic therapy to the spinal cord as well as the brain should be considered in the treatment of patients with small cell carcinoma of the lung.
Hodgkin's disease and non‐Hodgkin's lymphoma in children and young adults: A clinicopathologic study of 127 cases
Authors: Padmalatha Chandrashekar , Ganick Dorothy J. , Hafez Gholam‐Reza , Gilbert Enid F. 
Published: February 2007

AbstractOne hundred twenty‐seven cases of non‐Hodgkin's lymphoma and Hodgkin's disease in children and young adults at the University of Wisconsin Hospital between 1969 and 1980 have been reviewed. Nodular sclerosing was the most frequent histologic type in patients with Hodgkin's disease. Malignant lymphoblastic lymphoma (MLLB) was the most common type of non‐Hodgkin's lymphoma. The relationship of the histological pattern to age and sex as well as clinical behavior and survival are discussed.